Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions? Sometimes, but clinical judgement is more important than predefined criteria Andrea Apolo, M.D. Shilpa Gupta joaquim bellmunt Jonathan Rosenberg MD Michiel van der Heijden & Lisa Cordes gbr01.safelinks.protection.outlook.com/?url=https%3A%…

urothelial cancer highlight #ESMO24 New ADC data (1st line DV/pembo, EGFR/HER3),TAR200 (pretzel) in MIBC (SUNRISE4), EV/pembro biomarkers (EV302), adjuvant (TOMBOLA) and neoadjuvant (VOLGA) ctDNA, updates on adjuvant pembro (AMBASSADOR), neoadjuvant chemo +/- durvalumab (NIAGRA)

Out today in TIME — a review of recent advances in #KidneyCancer treatment highlighting the incredible work of Toni Choueiri, MD Dana-Farber Lank Center for Genitourinary Oncology Brian Rini, MD Vanderbilt Hem / Onc william huang nyulmc Katie Spina (she/her) Columbia RadOnc George R Schade Fred Hutchinson Cancer Center and many others! It takes a village to

Thank you to Society for Immunotherapy of Cancer and Melanoma Research for supporting our research!

Out in Journal of Clinical Oncology our next piece of the neoadjuvant puzzle in muscle-invasive #bladdercancer. Taxanes could be another good choice of backbone chemo to combine with IO, overcoming the known limits of platinum. #NureCombo provided Nivo/ABX x4 > RC > adj Nivo x13. N=31. 22 pts

Men whose fitness level improved by 3% or more annually over several years were 35% less likely to develop prostate cancer than men whose fitness declined, a study finds. nbcnews.com/health/cancer/…

Great paper on the performance of HER2 molecular imaging for met. breast Cancer! Congrats to the team Elisabeth de Vries JNM The interlesional heterogeneity of HER2 expression is remarkable! E.g. one third of patients with a HER2-negative or -low metastasis biopsy

You can still register to vote ahead of the U.S. general election! Health care professionals bring unique insights from serving their communities, and your voices need to be heard at the ballot box! brnw.ch/21wMuqQ #GOTV #ASCOAdvocacy

#ESMO24 begins this Friday and we will be presenting the latest findings from our PATCH, STAMPEDE and STAMPEDE2 #ClinicalTrials in #ProstateCancer. 📍Are you attending? We've put together a helpful guide to all our presentations and posters👇 mrcctu.ucl.ac.uk/news/news-stor…

Grateful for 8 wonderful years at the Cleveland Clinic Cleveland Clinic Lerner Research Institute. I will miss my amazing colleagues. So excited for the next adventure at Fred Hutchinson Cancer Center University of Washington Radiation Oncology!

☢️ Systematic review and meta-analysis of SABR in oligoprogression published in Radiotherapy & Oncology authors.elsevier.com/c/1jkuTcA0-IX1E Joelle Dr. David Palma Aisling Barry Jacques Raphael

Just in The Lancet Oncology 👉Zr-girentuximab PET–CT is highly accurate for detecting ccRCC #kidneycancer (like PSMA-PET in prostate ca) Congrats, Brian Brian Shuch, MD et al, on these practice-impacting data. Open access👉tinyurl.com/4cwkm8u5 Michael Morris OncoAlert UroToday.com

Paper out- TLX-250cdx as a tool to help patients with renal masses! also excited to have high risk postop staging protocol open too (Canine). UCLA Urology . Kidney Cancer KCCure KidneyCAN Kidney Cancer Canada YUO thelancet.com/journals/lanon… clinicaltrials.gov/study/NCT06447…

Completely agree. Our under-reviewed study found that 90% of Medicare Advantage PD and 70% of PDP patients require prior authorization just to get standard generic zofran tablets (not even ODT).... It only costs insurance $20ish for 1 month supply...

I feel this deeply. As a Mexican American immigrant & naturalized US citizen it’s hard to hear the degrading rhetoric surrounding immigrants. Creating irrational fears aimed at division, anger, & hate. We are stronger together. #Fightmisinformation #PresidentialDebate2024

Vote.org is a non-partisan, non-profit organization that is committed to ensuring every eligible 🇺🇸 voter has the tools they need to vote. Even if you are sure you’re registered, verify it here in under a minute. Bookmark & share. #Election2024 #vote

🚨 Start prepping for #ESMO2024 with half of TwoOncDocs Samantha Armstrong's round-up of #abstracts to keep an eye on in the #prostatecancer #UC, #MIBC, and #RCC spaces. 👀 Read more: buff.ly/4cZzFdN

Addressing uncertainties in the management of urothelial and renal cell carcinomas. What is the role of rechallenge with the same class of agents in advanced disease? Looking forward to this presentation by ylt Sat, 9/14 at #ESMO24!

Congrats to Pedro C Barata, MD MSc FACP Sumanta K. Pal, MD, FASCO and the entire team for the final OS analysis from the PAPMET trial! Though there is no significant OS difference, cabozantinib remains a solid option for advanced Papillary RCC. The need for novel therapies is clear! ASCO Journal of Clinical Oncology @oncoalert

So proud of Cristiane D Bergerot - after a stellar talk at #WCLC24, she is headed to #ESMO24 to educate us once again. Hard to find someone who works harder to advance #supportivecare. Neeraj Agarwal, MD, FASCO Petros Grivas Toni Choueiri, MD Shilpa Gupta Shuchi Gulati MD Matthew Loscalzo, LCSW City of Hope